|Bid||66.00 x 900|
|Ask||69.32 x 800|
|Day's Range||68.47 - 72.59|
|52 Week Range||26.02 - 72.59|
|Beta (3Y Monthly)||1.84|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||61.83|
Novocure (NVCR) today announced the U.S Centers for Medicare & Medicaid Services (CMS) has established a 2019 monthly fee schedule amount for Optune. The announcement by CMS follows an announcement earlier this morning by the durable medical equipment (DME) Medicare Administrative Contractors (MACs) that a final local coverage determination (LCD) providing coverage, effective September 1, 2019, of Optune for Medicare beneficiaries with newly diagnosed glioblastoma (GBM) has been established. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields.
NovoCure (NVCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novocure (NVCR) today announced the Medicare durable medical equipment (DME) Medicare Administrative Contractors (MACs) have released a final local coverage determination (LCD) providing coverage of Optune for Medicare beneficiaries with newly diagnosed glioblastoma (GBM) effective September 1, 2019. The final LCD and a summary response to comments are available in the U.S. Centers for Medicare & Medicaid Services (CMS) coverage database. “We are extremely pleased that CMS has established coverage of Optune for patients with newly diagnosed GBM and that many of the restrictions originally proposed were removed in response to public comment,” said Bill Doyle, Novocure’s Executive Chairman.
Capturing a powerful move in a short time is one of the main goals of swing trading. Novocure stock provides an example of a recent swing trade.
CEO of Novocure Ltd (NASDAQ:NVCR) Asaf Danziger sold 187,500 shares of NVCR on 06/28/2019 at an average price of $62.15 a share.
Novocure announced today that it will report financial results for the second quarter 2019 on Thursday, July 25, 2019, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three months ended June 30, 2019, at 8 a.m.
Novocure (NVCR) today announced that the German Institute for Quality and Efficiency in Healthcare, or IQWiG, has published its rapid report concluding that, based on a review of Novocure’s EF-14 phase 3 pivotal trial, patients with newly diagnosed glioblastoma (GBM) lived longer when treated with Optune in addition to standard chemotherapy, without affecting quality of life. This positive conclusion is an important step in Novocure’s process to secure national reimbursement for Optune in Germany.
Mid-caps stocks, like NovoCure Limited (NASDAQ:NVCR) with a market capitalization of US$5.7b, aren’t the focus of most...
CEO of Novocure Ltd (NASDAQ:NVCR) Asaf Danziger sold 190,338 shares of NVCR on 06/18/2019 at an average price of $59.37 a share.
During the Lightning Round of "Mad Money" Monday, Jim Cramer had this to say about cancer cure company Novocure Ltd. : "I think this is fantastic." The charts of NVCR are pretty strong, so we want to be a buyer. In this daily bar chart of NVCR, below, we can see can see a clear pattern of higher lows and higher highs -- the simple definition of an uptrend.
Is NovoCure Limited (NASDAQ:NVCR) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after adjusting for known risk attributes. […]
The cancer-focused medical-device maker received the go-ahead to enter a brand-new market. Here's why the news should make investors giddy.
In 2002 Asaf Danziger was appointed CEO of NovoCure Limited (NASDAQ:NVCR). This report will, first, examine the CEO...
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs May 23.) ArQule, Inc. (NASDAQ: ARQL ) Turning Point ...
Novocure (NVCR) announced today that Bill Doyle, Novocure’s Executive Chairman, will participate in the Jefferies 2019 Global Healthcare Conference on June 4, 2019, in New York City. Mr. Doyle will also participate in one-on-one meetings with investors throughout the day. A live audio webcast of the presentation can be accessed from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations, and will be available for replay for at least 14 days following the events.
Novocure (NVCR) today announced that the U.S. Food and Drug Administration (FDA) has approved the NovoTTF-100L System in combination with pemetrexed plus platinum-based chemotherapy for the first-line treatment of unresectable, locally advanced or metastatic, malignant pleural mesothelioma (MPM). NovoTTF-100L is a non-invasive, antimitotic cancer treatment that delivers Tumor Treating Fields to the region of the tumor.
Novocure (NVCR) today announced the Medicare durable medical equipment (DME) Medicare Administrative Contractors (MACs) have issued a proposed local coverage determination (LCD) that provides coverage of Tumor Treating Fields, or Optune, for newly diagnosed glioblastoma (GBM). Proposed LCDs are subject to a 45-day public comment period during which the DME MACs will consider feedback from patients, advocacy groups, prescribers and the general public prior to finalizing the LCD. The coverage policy criteria proposed by the DME MACs is generally similar to Optune’s commercial coverage criteria for newly diagnosed glioblastoma (GBM) with the exception of a proposed restriction on beneficiary site of care.